Table 2.
Tumor cell line characterization.
| Tumor type | Cell line | TRAIL-R2-relative MFIa | sTRAIL sensitivityb |
|---|---|---|---|
| Melanoma | Me15 | 103.8 | Sensitive |
| Me41 | 103.8 | Semi-sensitive | |
| Me64 | 3.8 | Resistant | |
| Me71 | 17.5 | Resistant | |
| Me79 | 42.5 | Resistant | |
| Prostate carcinoma | PC3 | 111.5 | Sensitive |
| LNCaP | 603.3 | Resistant | |
| DU145 | 694.0 | Sensitive | |
| Ovarian carcinoma | SK-OV-3 | 8.4 | Resistant |
| NL-3507 | 7.1 | Sensitive | |
| A2780 | 11.9 | Resistant | |
| A2774 | 16.4 | Semi-sensitive | |
| Cervix carcinoma | HeLa | 3.4 | Resistant |
| Epidermoid carcinoma | A431 | 6.7 | Semi-sensitive |
| Hepatocellular carcinoma | HepG2 | 168.0 | Sensitive |
| Colon carcinoma | Caco-2 | 308.1 | Resistant |
| Breast carcinoma | MDA-MB-231 | 10.3 | Sensitive |
| MT-3 | 12.2 | NA | |
| MDA-MB-468 | −0.1 | Sensitive | |
| BT-474 | 0.1 | Resistant |
a
MFI, mean fluorescence intensity evaluated by FACS analysis.
b
Evaluated by tumor growth inhibition assay using 100 ng/mL sTRAIL. The growth inhibition percentage allows to distinguish resistant (<30%), semi-sensitive (30–50%) and sensitive (>50%) cell lines. NA, not available.